Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug developed at UC Davis may prevent breast cancer, treat post-menopausal vaginal atrophy

03.11.2005


20-year collaboration between UC Davis and Finnish researchers led to new drug



A tamoxifen-like drug developed by UC Davis and Finnish researchers, now in clinical testing as a treatment for vaginal atrophy, may also help to prevent breast cancer, two preliminary studies suggest.

The studies, based on research in a mouse model of human breast cancer, will be published in the November issue of the Journal of Steroid Biochemistry and Molecular Biology and the December issue of Breast Cancer Research.


"These reports indicate that prevention of breast cancer may be another benefit of the use of ospemifine," said Michael W. DeGregorio, a professor of medicine at UC Davis. "The findings are very encouraging."

DeGregorio is senior author of the November article and a contributing author of the December paper. He has spent the last 20 years developing ospemifene in collaboration with Risto Lammintausta, managing director of Hormos Medical Corp. in Turku, Finland.

Ospemifene is now being developed by QuatRx Pharmaceuticals, an Ann Arbor, Mich.-based biopharmaceutical company that recently merged with Hormos Medical Corp. The drug is expected to enter Phase 3 clinical testing in the United States early next year for the treatment of vaginal atrophy, a common condition among postmenopausal women.

Ospemifene is one of a class of drugs called selective estrogen receptor modulators. The well-known agent tamoxifen, used to prevent breast cancer in women at high risk for the disease, and raloxifen, currently used to prevent bone fractures in women with osteoporosis, belong to the same class.

In the Journal of Steroid Biochemistry and Molecular Biology, DeGregorio and his colleagues at UC Davis compared the ability of ospemifene, tamoxifen and raloxifen to inhibit breast cancer in mice exposed to a carcinogen. Ospemifene and tamoxifen both inhibited breast cancer development: Mice in the ospemifene group were 95 percent less likely than mice in the control group to develop breast cancer. Raloxifen had no such effect. The study is available online in advance of its publication in print at www.sciencedirect.com.

The second study, led by Jeffrey P. Gregg, an associate professor of pathology and laboratory medicine at UC Davis, reports that in a mouse model, both tamoxifen and ospemifene inhibited the growth and progression of pre-malignant breast lesions that closely resemble human ductal carcinomas in situ. Both these agents decreased the growth of the lesions by reducing the proliferation rate of the precancerous cells.

The article is available online in advance of its print publication date at www.breast-cancer-research.com.

While similar, tamoxifen, raloxifen and ospemifine have variations in chemical structure that give them unique therapeutic profiles. For example, raloxifen can prevent bone fractures, but it can also cause hot flashes, insomnia and blood clots. Tamoxifen can decrease a high-risk woman’s odds of developing breast cancer by half, but the drug also increases the risk of endometrial cancer and can cause the same side effects as raloxifen.

In clinical tests so far, ospemifene appears to have a unique estrogen-like effect on the vagina, yet a neutral effect on the endometrium, or lining of the uterus, and no aggravation or initiation of hot flashes. Results of the Phase 1 and Phase 2 tests, conducted in postmenopausal women in Finland, appear in the journal Menopause in September 2003 and March 2005.

"Dr. Lammintausta and I worked for many years to find a drug that would have beneficial effects in healthy, postmenopausal women but be absolutely safe," said DeGregorio. "We’re gratified that this seems to be the case."

Decreased estrogen levels can lead to a thinner, less elastic and more fragile vaginal lining. Known as vaginal atrophy, the problem affects 10 to 40 percent of post-menopausal women. Symptoms may include dryness, itching, burning, irritation, a feeling of pressure, and pain or light bleeding with sex. Estrogen creams, rings, patches or oral supplements are often prescribed to treat vaginal atrophy.

Claudia Morain | EurekAlert!
Further information:
http://www.ucdmc.ucdavis.edu

More articles from Life Sciences:

nachricht A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht On the way to developing a new active ingredient against chronic infections
21.08.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Stretchable biofuel cells extract energy from sweat to power wearable devices

22.08.2017 | Power and Electrical Engineering

New technique to treating mitral valve diseases: First patient data

22.08.2017 | Medical Engineering

IVAM Marketing Prize recognizes convincing technology marketing for the tenth time

22.08.2017 | Awards Funding

VideoLinks
B2B-VideoLinks
More VideoLinks >>>